131 results about "Hepatic inflammation" patented technology

The invention relates to an Akecman mucophilic protein strain LWHK0003, which has the effects of preventing non-alcoholic steatohepatitis, resisting obesity, preventing NASH induced by GAN diet, maintaining constant blood sugar and resisting inflammation.

The present invention relates to a composition for inducing liver disease in a mammal and a mammal with a liver disease induced using the same. The animal model of the present invention has been found to be an excellent animal model in which fatty liver, hepatic fibrosis, and insulin resistance are evenly induced, and which successfully reproduces the progression of a series of severe liver diseases, from hepatitis and excessive fibrogenesis in liver tissue through tissue hardening (cirrhosis) to liver cancer, and reflects the characteristics of each stage with high reliability. Accordingly, the present invention may be useful as a means for developing a therapeutic agent for chronic liver disease as well as studying the molecular and circulatory mechanisms of each stage of liver disease.

The invention discloses multi-component inulin hydrogel as well as a preparation method and application thereof, and belongs to the technical field of nano materials and medicines.The multi-component inulin hydrogel is characterized in that a medicine L-alanyl-L-glutamine contributing to intestinal mucosa repair is entrapped in the inulin hydrogel; the multi-component inulin hydrogel has the advantages that the multi-component inulin hydrogel is prepared from the inulin and composite nanoparticles (namely mesoporous polydopamine-gallium composite nanoparticles) composed of an active oxygen scavenger polydopamine and an antibacterial agent gallium ions, the repairing capacity on intestinal barriers is further enhanced, and the prepared multi-component inulin hydrogel can be used for effectively treating inflammatory bowel diseases and non-alcoholic steatohepatitis.

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

The invention discloses application of a substance taking MANF as a target spot in preparation of a medicine for treating non-alcoholic steatohepatitis. The research finds that the expression of the MANF in liver tissues of a fatty liver patient and a non-alcoholic steatohepatitis model mouse is obviously up-regulated, and the weight, liver lipid accumulation and inflammatory infiltration of the NASH mouse can be obviously reduced by specifically knocking out the MANF by the macrophage, so that the MANF in the macrophage plays an important role in the NASH pathological process.

The invention discloses a method for exploring the influence of hepatic hydatid on hepatitis, and belongs to the technical field of medical research. The method comprises the following steps: selecting liver echinococcosis cases and viral hepatitis cases from hospitals in areas with high incidence of echinococcosis; collecting detailed medical history data of the screened case patients; counting the collected data, establishing a database, comparing various index differences of hepatic hydatid combined hepatitis cases and pure viral hepatitis cases, and preliminarily analyzing the influence of hepatic hydatid on hepatitis; selecting a research object and pairing patients in a control group; establishing a follow-up visit queue, and regularly carrying out follow-up visit on the research object and the control group patients; and counting follow-up data of the research object and the control group of patients, and analyzing the influence of the hepatic hydatid on the hepatitis. According to the method for exploring the influence of the hepatic hydatid on the hepatitis, the influence of the hepatic hydatid on the hepatitis is comprehensively and deeply explored, and a powerful basis is provided for clinical diagnosis, treatment and prevention.

The present invention relates to the medical use of specific long-acting glycemic analogs having dual GLP-1 / glycemic receptor agonist activity for the prevention and / or treatment of metabolic liver diseases, in particular non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NAFLD-related hepatic fibrosis and / or cirrhosis.

The present invention discloses the application of the combined drug of mecobalamin (MeCbl) and Shuilinjia (SC) in the treatment of non-alcoholic steatohepatitis (NASH). The present invention firstly proposes that oral MeCbl can effectively intervene in and treat the progression of NASH disease, and firstly proposes that the combined drug of oral MeCbl and SC can synergistically enhance the treatment of NASH, as well as liver injury, inflammation, liver fibrosis and hepatic lipid deposition on the basis of monomeric drugs. The MeCbl / SC composition in the present invention has a potent effect on the treatment of NASH, provides a new therapeutic drug for such refractory liver diseases clinically, while reducing the single-drug use dose of SC, and reducing the incidence of adverse reactions and treatment costs of patients. The pharmacokinetics and safety data of the drug molecules involved in the present invention are relatively detailed, and the development of new indications can quickly enter clinical evaluation, saving development costs while shortening the R & D cycle.

The present invention relates to the technical field of liver-protecting formula compositions, and in particular, to a liver-protecting milk thistle formula composition, and a preparation method thereof. Technical problems: the liver-protecting milk thistle formula composition, and a preparation method thereof are intended to solve the technical problems that most of existing liver-protecting compositions in the prior art are designed for the general liver protection needs of the general population and cannot specifically treat liver damage caused by excessive alcohol intake and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia. Technical solution: a liver-protecting milk thistle formula composition, including the following components: silymarin, puerarin, artichoke extract, glutathione, dandelion extract, and GABA. The liver-protecting formula composition has a good therapeutic effect on liver damage caused by excessive alcohol intake, and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of LAP3 and an agonist thereof in macrophage immune inflammation mediated diseases. The invention provides application of leucine aminopeptidase 3 or leucine aminopeptidase 3 agonist substances in preparation of drugs for prevention, treatment and / or adjuvant treatment of macrophage immune inflammation mediated diseases. According to the invention, it is found for the first time that the expression level of LAP3 in macrophages is increased under an acute stress condition, and the limiting effect of LAP3 on generation and development of sepsis and acute hepatitis is disclosed; the invention discloses that the knockout of the LAP3 can remodel a macrophage metabolic network, reduce oxidative phosphorylation, promote ROS (reactive oxygen species) production and activate TAK1, thereby promoting the activation of a downstream inflammation signal channel and finally promoting macrophage inflammation. A new target spot and a theoretical basis can be provided for clinical diagnosis and treatment of macrophage-mediated inflammation by illuminating the effect of LAP3 on regulating and controlling macrophage inflammation and a molecular mechanism of LAP3.

The present invention pertains to a method or a pharmaceutical composition of new ovatodiolide derivative compounds, AR100-RA1-Cys and AR100-RA1-ST, which have shown unexpected effects in treating autoimmune diseases, characterized by hepatocellular inflammation, such as autoimmune hepatitis, diabetes mellitus type 1, Sjogren's syndrome, multiple sclerosis and psoriasis. Also provided are the synthetic processes for compound preparation.

The present invention relates to food and pharmaceutical compositions for relieving endoplasmic reticulum stress to suppress or prevent various diseases caused by endoplasmic reticulum stress. More specifically, the present invention relates to a food and pharmaceutical composition for preventing or treating fatty liver symptoms or hepatitis, comprising a lysate of any one selected from the group consisting of Saccharomyces cerevisiae KCTC 13925BP, KCTC 14122BP, KCTC 14123BP, KCTC 14983BP, KCTC 14984BP, and KCTC 14985BP, or a mixture thereof.

The present disclosure relates to RNAi agents, e.g., double-stranded RNAi agents, capable of inhibiting the expression of a mitochondrial amidoxime reducing component 1 (MARC1) gene. Also disclosed are pharmaceutical compositions comprising the MARC1 RNAi agent and methods of using the same. In some embodiments, the MARC1 RNAi agents disclosed herein can be conjugated to targeting ligands, including ligands comprising N-acetyl-galactosamine, to facilitate delivery to hepatocytes. Delivery of the MARC1 RNAi agent in vivo provides inhibition of MARC1 gene expression. RNAi agents may be used in methods of treating diseases, disorders or conditions mediated in part by MARC1 gene expression, including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease, autoimmune hepatitis, hepatic fibrosis, cirrhosis, elevated blood cholesterol levels, hypertriglyceridemia, liver disease, and / or other MARC1 related diseases.

The invention provides application of a stevia rebaudiana extract, and belongs to the technical field of pure natural plant extracts, the stevia rebaudiana extract at least contains phenols, flavones and potassium ions, and when a health care product and / or a composition are given to a subject, at least one of the following components is achieved: antioxidant activity, antioxidant activity, antioxidant activity, antioxidant activity, antioxidant activity, antioxidant activity, antioxidant activity and the like. The expression of IRS protein, tyrosine phosphorylation of IRS and the content of GLUT4 protein are increased; bacteria are inhibited, and viruses and allergy are resisted; the intraocular pressure is reduced; the appetite is promoted; the hair loss is prevented or the hair growth is promoted. The application comprises application of the stevia rebaudiana extract in preparation of hair loss preventing or hair growth promoting products. The health-care product containing the stevia rebaudiana extract can prevent or treat type 2 diabetes mellitus, inhibit bacteria or resist viruses or allergy, and can be used as auxiliary food and / or sports food for sub-health people, type 2 diabetes mellitus patients, patients receiving glaucoma treatment, cancer patients, hepatitis patients, overweight people, picky and anorexia children or patients during general disease rehabilitation. The hair loss can be prevented or the hair growth is promoted.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

The present disclosure provides compounds of Formula I and pharmaceutically acceptable salts, solvates, and / or derivatives thereof. In addition, the disclosure also provides methods of treating a disease, disorder or condition mediated by SHIP1 or treatable by SHIP1 activation comprising administering a compound of Formula I or a pharmaceutically acceptable salt, solvate or derivative thereof. The compounds of Formula I, or pharmaceutically acceptable salts, solvates, or derivatives thereof, are useful for the treatment of SHIP1 mediated diseases, disorders, or conditions, including inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, multiple myeloma, liver injury, acute hepatitis, and severe sepsis.

The application provides an optimized lactoferricin peptide, a preparation method thereof and application thereof in preparation of anti-inflammatory and anti-oxidative damage preparations, and belongs to the technical field of biological medicines.The application obtains high-biological-activity lactoferricin peptide by optimizing amino acid sites of lactoferricin B; compared with the original lactoferricin B, the optimized lactoferricin peptide has better anti-inflammatory and anti-oxidative effects, can effectively reduce alcohol-induced oxidative damage, fatty degeneration and apoptosis of liver cells, and promote recovery of liver function.The lactoferricin peptide provided by the application can reduce the elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels by about 25% and 20%, respectively.The application provides an application scheme in development of a new generation of polypeptide drugs for treating alcoholic liver disease, hepatitis, acute lung injury and various inflammation oxidative stress related diseases.

The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.

The invention specifically discloses a novel chalcone compound as well as a preparation method, a pharmaceutical composition and application thereof. Experimental results show that the compound shows remarkable anti-inflammatory activity in a lipopolysaccharide stimulated RAW 264.7 cell model, and the anti-inflammatory activity is obviously superior to that of a positive drug dexamethasone; the compound shows a remarkable lipid accumulation inhibition effect in a HepG2 cell model treated by free fatty acid, is obviously superior to a positive drug obeticholic acid, and can be used for developing drugs for treating the non-alcoholic fatty liver disease, including but not limited to simple fatty liver, non-alcoholic steatohepatitis and related liver cirrhosis.

The present invention provides an antibody comprising citrulline epitope or a binding fragment thereof for use in the treatment or prevention of a disease associated with release of an extracellular trap from a cell, such as a neutrophil extracellular trap (NET)-associated disease (NET-associated disease) or an eosinophil extracellular trap (EET)-associated disease (EET-associated disease), the method comprises administering at least one dose of an antibody at a specific concentration. The present invention also provides these methods themselves. NET related diseases include systemic lupus erythematosus (SLE), lupus, septicemia, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, and the like. Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulogenic uveitis, granulogenic uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The invention also provides a pharmaceutical composition and a method for treating or preventing NET related diseases. Such as SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, Parkinson's disease, Lewy body dementia, asthma, and the like. Allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulometric uveitis, granulometric uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The EET-related diseases include eosinophilic granulocyte diseases or conditions, such as eosinophilic granulocyte diseases or conditions of skin; a respiratory eosinophilic granulocyte disease or condition; gastrointestinal eosinophilic cell diseases or disorders; allergic diseases or conditions; or worm, fungus, virus or bacterial infection.

The invention discloses an application of a compound as a CYP2E1 inhibitor, which is characterized in that the compound or a salt thereof as an inhibitor takes CYP2E1 as a target spot and is combined with the CYP2E1, and the CYP2E1 inhibitor has an inhibition effect on CYP2E1. The inhibitor can be used for preventing and treating tumors such as liver cancer, glioma, ovarian cancer, bladder cancer and gallbladder cancer. Similarly, the inhibitor can also be used for preventing and treating other inflammation-related diseases such as liver injury, fatty liver, hepatitis, hepatic fibrosis, rheumatic and rheumatoid arthritis, sepsis, Alzheimer's disease, ischemic cerebral apoplexy, Parkinson's disease, hyperlipidemia, atherosclerosis, coronary heart disease, diabetes mellitus and the like.

To provide RNAi agents for inhibiting expression of the α-1 antitrypsin (AAT) gene, compositions including the AAT RNAi agents, and methods of using the same.SOLUTION: Also there are disclosed pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agents to living cells in vivo. The delivery of the AAT RNAi agents to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.SELECTED DRAWING: Figure 9

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation and / or fibrosis in the liver, e.g., metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), primary biliary cholangitis, primary sclerosing cholangitis, alcoholic cirrhosis, hepatitis cirrhosis, cholestasis, autoimmune hepatitis, viral hepatitis B, viral hepatitis C, hemochromatosis, Wilson's disease, or alcoholic steatohepatitis, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

The invention relates to compounds of formula I wherein R1, R2, R3, A, D, E, G, J, K and L are as defined in claim 1; as well as prodrugs, deuterated analogs and pharmaceutically acceptable salts thereof; the compounds are useful in the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferon lesions, non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). # imgabs0 #

This invention discloses a ginsenoside Rg5 derivative with the molecular formula: C 42 H 74 O 12 The molecular weight is 770.5180. Furthermore, this invention also discloses the synthesis method and application of this derivative. The synthesis method of this invention is simple and safe, and the synthesized ginsenoside Rg5 derivative exhibits strong stability and superior therapeutic effect on non-alcoholic steatohepatitis (NAH). This invention is the first to combine the prepared ginsenoside Rg5 derivative with the PDE4 inhibitor (R)-(-)-Rolipram, showing significantly better efficacy than either drug alone. When the molar ratio of the two drugs is 1:1, the drug exhibits even better therapeutic effect on NHA, showing promising application prospects.

The present invention relates to food and pharmaceutical compositions that alleviate endoplasmic reticulum stress and thereby suppress or prevent various diseases caused by endoplasmic reticulum stress. More specifically, the present invention relates to food and pharmaceutical compositions for preventing or treating symptoms of fatty liver or hepatitis, which contain a lysate of any one selected from the group consisting of Saccharomyces celloviciae KCTC13925BP, KCTC14122BP, KCTC14123BP, KCTC14983BP, KCTC14984BP, and KCTC14985BP, or a mixture thereof.

The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives of Formula (I): or a salt or prodrug thereof. These compounds are TLR9 inhibitors useful for the treatment, prevention or slowing of a fibrotic disease, such as liver fibrosis, kidney fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic nephropathy, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

The present invention relates to the use of a cell-free fat extract for the treatment of non-alcoholic steatohepatitis. Specifically, the present invention provides a use of the cell-free fat extract for preparing a composition or formulation for preventing and / or treating non-alcoholic steatohepatitis. The cell-free fat extract of the present invention has excellent therapeutic effects on non-alcoholic steatohepatitis.

The application discloses strigasiaticaside A and an extraction method and application thereof, and finds, through chemical component research on the whole grass of striga asiatica, a new synbinaphthyl tetrahydrofuran lignan glycoside, that is, strigasiaticaside A, identifies the chemical structure of the new compound through nuclear magnetic resonance, mass spectrometry, ultraviolet, infrared and circular dichroism spectrum technology.The structure of the new compound is identified as (-) sesamin-5-O-beta-D-glucopyranoside.The anti-hepatitis activity of the new natural product is evaluated by using LPS stimulated HepG2 cells.The results show that when the concentration is 100 muM, the compound has a significant inhibitory effect on the production of inflammatory factors IL-10 and NF-kappa B protein, and has no cytotoxicity, indicating that the compound may have potential anti-hepatitis activity.